Latest Insider Transactions at Cvs Health Corp (CVS)
This section provides a real-time view of insider transactions for Cvs Health Corp (CVS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CVS HEALTH Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CVS HEALTH Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2018
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
797
+1.92%
|
$53,399
$67.73 P/Share
|
|
Feb 27
2018
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
197
-0.5%
|
$13,396
$68.25 P/Share
|
|
Feb 20
2018
|
David M Denton EVP and CFO |
SELL
Other acquisition or disposition
|
Direct |
18,057
-49.53%
|
-
|
|
Feb 20
2018
|
David M Denton EVP and CFO |
SELL
Other acquisition or disposition
|
Direct |
38,836
-25.4%
|
-
|
|
Feb 16
2018
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
19,965
-30.68%
|
$1,417,515
$71.04 P/Share
|
|
Feb 16
2018
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
19,965
+23.48%
|
$898,425
$45.07 P/Share
|
|
Dec 21
2017
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Open market or private sale
|
Direct |
29,445
-65.43%
|
$2,208,375
$75.0 P/Share
|
|
Nov 08
2017
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,630
+16.48%
|
$110,840
$68.99 P/Share
|
|
Nov 08
2017
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,521
+13.91%
|
$103,428
$68.99 P/Share
|
|
Nov 08
2017
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,131
+4.89%
|
$280,908
$68.99 P/Share
|
|
Nov 08
2017
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,521
+50.0%
|
$103,428
$68.99 P/Share
|
|
Nov 08
2017
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,521
+5.84%
|
$103,428
$68.99 P/Share
|
|
Oct 02
2017
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
20,547
-47.59%
|
$1,664,307
$81.17 P/Share
|
|
Oct 02
2017
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,547
+32.24%
|
-
|
|
Sep 18
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
85,743
-71.72%
|
$7,116,669
$83.14 P/Share
|
|
Sep 18
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
85,743
+41.77%
|
$2,915,262
$34.96 P/Share
|
|
Sep 15
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
39,340
-46.65%
|
$3,186,540
$81.88 P/Share
|
|
Sep 15
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
39,340
+31.81%
|
$2,124,360
$54.53 P/Share
|
|
Sep 13
2017
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
241,150
-44.62%
|
$20,015,450
$83.07 P/Share
|
|
Sep 13
2017
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
241,150
+30.86%
|
$8,199,100
$34.96 P/Share
|
|
Sep 11
2017
|
Thomas M Moriarty EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
90,267
-60.76%
|
$7,131,093
$79.61 P/Share
|
|
Sep 11
2017
|
Thomas M Moriarty EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
90,267
+37.78%
|
$4,603,617
$51.6 P/Share
|
|
Sep 11
2017
|
David M Denton EVP and CFO |
SELL
Open market or private sale
|
Direct |
237,078
-54.64%
|
$18,729,162
$79.64 P/Share
|
|
Sep 11
2017
|
David M Denton EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
108,183
+42.86%
|
$5,841,882
$54.53 P/Share
|
|
Aug 23
2017
|
Larry J Merlo Director |
SELL
Bona fide gift
|
Direct |
14,163
-4.52%
|
$1,090,551
$77.61 P/Share
|
|
Aug 16
2017
|
Richard J Swift Director |
SELL
Open market or private sale
|
Direct |
2,500
-43.42%
|
$197,500
$79.62 P/Share
|
|
Jun 26
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
20,333
-31.12%
|
$1,626,640
$80.0 P/Share
|
|
Jun 26
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
20,333
+13.94%
|
$691,322
$34.96 P/Share
|
|
Jun 19
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
SELL
Open market or private sale
|
Direct |
20,332
-31.12%
|
$1,545,232
$76.98 P/Share
|
|
Jun 19
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Exercise of conversion of derivative security
|
Direct |
20,332
+13.94%
|
$691,288
$34.96 P/Share
|
|
Jun 12
2017
|
David M Denton EVP and CFO |
SELL
Open market or private sale
|
Direct |
230,510
-58.35%
|
$18,440,800
$80.0 P/Share
|
|
Jun 12
2017
|
David M Denton EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
230,510
+18.57%
|
$9,220,400
$40.1 P/Share
|
|
May 10
2017
|
David W Dorman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,521
+4.42%
|
$281,680
$80.94 P/Share
|
|
May 10
2017
|
Nancy Ann Deparle Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,297
+14.11%
|
$103,760
$80.94 P/Share
|
|
May 10
2017
|
Richard M Bracken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,389
+17.31%
|
$111,120
$80.94 P/Share
|
|
May 10
2017
|
Jean Pierre Millon Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,297
+50.0%
|
$103,760
$80.94 P/Share
|
|
May 10
2017
|
Tony L White Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,297
+5.34%
|
$103,760
$80.94 P/Share
|
|
Apr 03
2017
|
Robert O. Kraft EVP and President - Omnicare |
BUY
Grant, award, or other acquisition
|
Direct |
5,124
+5.26%
|
$399,672
$78.05 P/Share
|
|
Apr 03
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,624
+26.58%
|
$1,998,672
$78.05 P/Share
|
|
Apr 03
2017
|
Helena Foulkes EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
19,218
+27.29%
|
$1,499,004
$78.05 P/Share
|
|
Apr 03
2017
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
43,241
+19.02%
|
$3,372,798
$78.05 P/Share
|
|
Apr 03
2017
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
16,015
+26.83%
|
$1,249,170
$78.05 P/Share
|
|
Apr 03
2017
|
David M Denton EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
12,812
+7.73%
|
$999,336
$78.05 P/Share
|
|
Apr 03
2017
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,609
+22.3%
|
$749,502
$78.05 P/Share
|
|
Apr 03
2017
|
Stephen J Gold EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct |
8,648
+15.59%
|
$674,544
$78.05 P/Share
|
|
Apr 03
2017
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,046
+23.39%
|
$549,588
$78.05 P/Share
|
|
Apr 03
2017
|
Andrew Sussman EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
4,804
+22.62%
|
$374,712
$78.05 P/Share
|
|
Apr 03
2017
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,484
+22.24%
|
$349,752
$78.05 P/Share
|
|
Apr 03
2017
|
J. David Joyner President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,484
+21.87%
|
$349,752
$78.05 P/Share
|
|
Apr 02
2017
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,655
-12.1%
|
$363,090
$78.5 P/Share
|